Ludwig Institute for Cancer Research Limited

Christophe Lurguin

Thierry R Boon-Falleur

Pierre Van Der Bruggen

Benoit Van Den Eynde

Etienne De Plaen

Catia Traversari

Beatrice Gaugler

The invention involves a nonapeptide derived from the tumor rejection antigen precursor encoded by gene MAGE-3. This nonapeptide is presented by the HLA molecule HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.

Method for screening for cancer using binders for MAGE related peptides and complexes of the peptide and HLA molecules

The invention involves a nonapeptide derived from the tumor rejection antigen precursor encoded by gene MAGE-3. This nonapeptide is presented by HLA molecules HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.

Isolated cytolytic T cells specific for complexes of MAGE related

Growing community of inventors

Brussels, Belgium

Christophe Lurguin